Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Phase 1/2 Completed 37 enrolled University of Michigan Rogel Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

This protocol is an open label, single arm, non-randomized, phase I / II clinical trial investigating the use of pegylated interferon alpha-2a (peg-IFN-α, Pegasys®, Genentech) for prevention of relapse in acute myeloid leukemia (AML) not in remission at the time of allogeneic hematopoietic stem cell transplantation (HCT).

Timeline

Start: 2015-01
Primary completion: 2019-03-25
Completion: 2019-03-25

Publications

Magenau JM, Peltier D, Riwes M, Pawarode A, Parkin B, Braun T, Anand S, Ghosh M, Maciejewski J, Yanik G, Choi SW, Talpaz M, Reddy P. Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021 Dec 14;5(23):5047-5056. doi: 10.1182/bloodadvances.2021004908.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	45 ug	Subcutaneous
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	90 ug	Subcutaneous
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	180 ug	Subcutaneous
Background	Methotrexate	Small molecule	—	—
Background	Tacrolimus	Small molecule	—	—

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications